Proprietary NANOLUTE technology ensures drug binding on the balloon and fast drug transfer to the tissue, as well as drug retention. Preclinical trials done by dr. Renu Virmani proving that Sirolimus is present in the vessel tissue 14 days post inflation in sufficient therapeutic doses. At the same time systemic drug loss is minimal. Additionally, the drug tissue presence is noted all the way up to adventitial layer.

NANOLUTE technology combines nanotechnology, in scaling down the drug and carrier particle size to nano-level in order to ensure drug uptake to the tissue, with special type of carrier which is helping to overcome low lipophilicity of Sirolimus as a limiting factor for successful drug binding on the balloon and transfer to the lesion.

The benefit of Sirolimus (or limus group) as an anti-proliferative drug compared to Paclitaxel is well known and documented in several DES trials. Main benefits include cytostatic mode of action (compared to cytotoxic of Paclitaxel) and better anti-restenotic effect.